EYLEA HD® and EYLEA® remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudited) results EYLEA HD ...
The drug stands out as the only one of its kind, with the potential not only to prevent the onset of skin cancer but also to treat early-stage conditions in organ transplant patients. The ...